# Gain Therapeutics to Present at the 38th Annual ROTH Conference
Canonical URL: https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-the-38th-annual-roth-conference-01a05c6e
Ticker: GANX
Company: Gain Therapeutics
Source: Gain Therapeutics
Published: 2026-03-19 20:57 EST
## Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

## Article Body
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38 th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA.

Fireside Chat Details

Date: Monday, March 23, 2026

Time: 11:30 a.m. PT

Access a live webcast or a replay of the fireside chat here or visit the “Investors & Media/News & Events” section of the Company’s website at https://gaintherapeutics.com .

If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact either your ROTH representative or ir@gaintherapeutics.com .

About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287 and GT-04686; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies and the timing of any responses from the FDA or other regulatory bodies and agencies; the timing of the commencement of any Phase 2 clinical studies for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates, including GT-02287 and GT-04686. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors: Gain Therapeutics, Inc. Apaar Jammu Director, Investor Relations and Public Relations ajammu@gaintherapeutics.com

LifeSci Advisors LLC Chuck Padala Managing Director chuck@lifesciadvisors.com

Media: Russo Partners LLC Nic Johnson and Elio Ambrosio nic.johnson@russopartnersllc.com elio.ambrosio@russopartnersllc.com (760) 846-9256
## Recent Company News
- 2026-07-16 11:00 EST — [Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-ceo-gene-mack-issues-letter-to-shareholders-and-provides-opera-8b796693) — Source: Gain Therapeutics
- 2026-06-29 20:05 EST — [Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease](https://biopharmsignal.com/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-11cfdeaf) — Source: Gain Therapeutics
- 2026-06-10 11:00 EST — [Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit](https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-exp-b322982c) — Source: Gain Therapeutics
- 2026-05-26 12:00 EST — [Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026](https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-positive-interim-data-from-phase-1b-clinical-study-of-7715a5b9) — Source: Gain Therapeutics
- 2026-05-11 11:00 EST — [Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-first-quarter-2026-and-provides--070df9ff) — Source: Gain Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)